亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Phase 1 study of PSCA-targeted chimeric antigen receptor (CAR) T cell therapy for metastatic castration-resistant prostate cancer (mCRPC).

作者
Tanya Barauskas Dorff,Suzette Blanchard,Hripsime Martirosyan,Lauren N. Adkins,Gaurav Dhapola,Aidan Moriarty,Jamie R. Wagner,Ammar Ahmed Chaudhry,Massimo D’Apuzzo,Peter Kühn,Stephen J. Forman,Saul J. Priceman
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:40 (6_suppl): 91-91 被引量:19
标识
DOI:10.1200/jco.2022.40.6_suppl.091
摘要

91 Background: Chimeric antigen receptor (CAR)-engineered T cell therapies are being pursued for the treatment of mCRPC. Prostate Stem Cell Antigen (PSCA) is highly expressed on the surface membrane in mCRPC and with limited expression on normal tissues. We undertook a phase 1, first-in-human study of a PSCA-targeted 4-1BB-co-stimulated CAR T cell therapy in mCRPC. Methods: CAR T cells were manufactured at City of Hope’s cGMP facility. The trial followed the Target equivalence range design with an equivalence range of.20-.35 and too toxic level of 0.51 following participants in cohorts of 3. The plan was to begin at a dose of 100 million (M) without lymphodepletion (LD) chemotherapy consisting of fludarabine and cyclophosphamide, then add LD to 100M prior to dose escalation to maximum 600M. Patients (pts) were required to have disease progression after at least 1 androgen receptor targeted therapy but there was no limit on prior chemotherapy or other treatments. Primary objective is to define the dose limiting toxicity (DLT) and recommended phase 2 dose as well as to describe preliminary bioactivity and efficacy. Correlative studies include MRI for target bone lesion response, CAR T cell persistence, circulating tumor cells, and serum cytokines. Results: 12 pts have been treated to date, median age 68 (42-72). Three pts were treated at the 100M dose with no DLTs. In the 100M plus LD dose level there 2 pts experienced DLT of grade 3 cystitis non-infective and fatigue. The protocol was amended to reduce the LD dose to 300 mg/m2 cyclophosphamide D1-3 and intensify monitoring with early intervention for cystitis. No DLT occurred in 3 pts treated in the modified LD 100M cohort. Cytokine release syndrome (CRS), DLTs and best response by RECIST are presented by dose level in the table. PSA declines (one >90%) were seen as well as radiographic improvement, though RECIST response was limited to stable disease (SD) by concurrent bone metastases. Correlative studies indicated bioactivity of PSCA-CAR T cells. Conclusions: PSCA-CAR T cell therapy is feasible in pts with mCRPC with DLT of cystitis, and shows preliminary anti-tumor effect at a dose of 100M plus LD. Dose escalation to 300M may proceed. Clinical trial information: NCT03873805. [Table: see text]

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Lucas的应助被369ninja采纳,获得10
5秒前
orixero的应助被369ninja采纳,获得10
20秒前
26秒前
努力努力再努力完成签到,获得积分10
34秒前
情怀的应助被369ninja采纳,获得10
35秒前
直率的宛丝完成签到,获得积分10
41秒前
humorlife完成签到,获得积分10
48秒前
现代的冰海完成签到,获得积分10
49秒前
49秒前
zyyicu完成签到,获得积分10
50秒前
希望天下0贩的0的应助被369ninja采纳,获得10
51秒前
霸气惜文完成签到,获得积分10
55秒前
大模型的应助被369ninja采纳,获得10
1分钟前
1分钟前
369ninja发布了新的文献求助10
1分钟前
懦弱的代云完成签到,获得积分10
1分钟前
如意涵雁完成签到,获得积分10
1分钟前
华仔的应助被爱学习的doge采纳,获得10
1分钟前
英姑的应助被爱学习的doge采纳,获得10
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
韩_发布了新的文献求助10
2分钟前
彭于晏的应助被科研通管家采纳,获得10
2分钟前
充电宝的应助被sun采纳,获得10
2分钟前
2分钟前
甜甜的文轩完成签到,获得积分10
2分钟前
爱笑的芝麻完成签到,获得积分10
2分钟前
阿双完成签到,获得积分10
2分钟前
sun发布了新的文献求助10
2分钟前
2分钟前
3分钟前
灵巧的绮琴完成签到,获得积分10
3分钟前
整齐的天问完成签到,获得积分10
3分钟前
Qian完成签到 ,获得积分10
3分钟前
细腻绮完成签到,获得积分10
3分钟前
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179956
求助须知:如何正确求助?哪些是违规求助? 9570170
关于积分的说明 21808444
捐赠科研通 7775818
什么是DOI,文献DOI怎么找? 3433251
关于科研通互助平台的介绍 2557352
邀请新用户注册赠送积分活动 2478958